IMAX Q2 Results Show Solid Box Office Expansion, But Valuation Remains Stretched

What happened

IMAX Corporation reported solid Q2 results driven by higher system installations and a favorable film slate, including the highly anticipated 'The Odyssey,' filmed entirely on IMAX 70mm cameras. The company continues to gain box office market share, bolstered by filmmaker interest and theater network expansion. However, at $35.13, the stock trades at ~48x trailing earnings and ~18x EV/EBITDA, pricing in record 2025 performance and near-perfect 2026 slate execution. The underlying business remains highly sensitive to tentpole fluctuations and China volatility, while the multiplex TAM of ~3,619 locations limits long-term unit growth. With limited margin of safety and downside risk to the mid-$20s if 2026 underperforms, current levels offer unfavorable risk-reward.

Implication

Investors should remain cautious; the bullish narrative is already priced in at ~48x trailing earnings, leaving limited margin of safety. The stock's ~49% appreciation over the past year already reflects the record 2025 box office and optimistic 2026 slate expectations, leaving little room for error. At $35.13, IMAX trades near the upper end of its fair value range (~$34 base case, $24 bear, $45 bull), implying downside skew absent flawless slate execution. The company's heavy dependence on a handful of tentpoles, China regulatory risk, and a relatively saturated target market cap the long-term growth narrative. While the Q2 results confirm near-term momentum, they do not de-risk the structural challenges highlighted in our analysis. We recommend trimming positions above $42 and look for a more attractive entry near $28 before re-engaging.

Thesis delta

The news reinforces the bullish short-term narrative around IMAX's box office momentum and slate quality, but it does not alter our core thesis that the stock is fully valued with limited upside. The second-quarter results, while solid, validate the existing positive sentiment rather than introduce new catalysts, leaving the risk-reward skewed to the downside. Our POTENTIAL SELL rating and conviction level remain unchanged, as the high multiple and cyclical exposure still outweigh the growth story.